| Active substance | alectinib |
| Holder | nv Roche sa |
| Status | Running |
| Indication | Alecensa as monotherapy is indicated as adjuvant treatment following complete tumour resection for adult patients with ALK-positive NSCLC at high risk of recurrence (see selection criteria). |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
Last update |
19/07/2024 |